# FABHALTA® (iptacopan) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/iptacopan

> The FDA approved FABHALTA® (iptacopan), sponsored by NOVARTIS AG (NVS), on Mar 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | FABHALTA® (iptacopan) |
| Codes | LNP023 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | To treat paroxysmal nocturnal hemoglobinuria, [Primary Immunoglobulin A Nephropathy (IgAN)](https://sec-api.dev/indications/primary-immunoglobulin-a-nephropathy-igan), [Atypical Hemolytic Uremic Syndrome](https://sec-api.dev/indications/atypical-hemolytic-uremic-syndrome), [Paroxysmal Nocturnal Hemoglobinuria](https://sec-api.dev/indications/paroxysmal-nocturnal-hemoglobinuria), [Generalized Myasthenia Gravis](https://sec-api.dev/indications/generalized-myasthenia-gravis), [IC-MPGN](https://sec-api.dev/indications/ic-mpgn), [IgA Nephropathy](https://sec-api.dev/indications/iga-nephropathy), Glomerulonephritis, IGA |
| Modality |  |
| FDA designations | priority review |

## Timeline

### December 5, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat paroxysmal nocturnal hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Fabhalta | iptacopan | 12/5/2023 | To treat paroxysmal nocturnal hemoglobinuriaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA218276 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20231205, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22

### August 7, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218276 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20240807, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22

### Mar 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-04-03, last confirmed 2025-04-03.
- SEC Form 8-K (accession 0001171843-25-001979): "This is the third US approval received by Novartis for its kidney disease portfolio in the last year, with Fabhalta® having been granted FDA approval in C3 glomerulopathy (C3G) in March 2025 and accelerated approval in IgAN in August 202415." https://www.sec.gov/Archives/edgar/data/1114448/000117184325001979/f6k_040325.htm

### March 20, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218276 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250320, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22

### September 19, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: IgA Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." https://clinicaltrials.gov/study/NCT04578834

### April 11, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Atypical Hemolytic Uremic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04889430 (Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-11 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04889430

### July 16, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218276 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20260716, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22

### November 4, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: IgA Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." https://clinicaltrials.gov/study/NCT04578834?tab=results

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06388941 (Iptacopan in Patients With ANCA Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06388941

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06388941 (Iptacopan in Patients With ANCA Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06388941

### Jan to Apr 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: C3G.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04817618 (Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04817618

### January 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: C3G.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04817618 (Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04817618

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06517758 (A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06517758

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Generalized Myasthenia Gravis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06517758 (A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06517758

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04747613 (Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04747613

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04747613 (Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT04747613

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Glomerulonephritis, IGA; Immunoglobulin A Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06797518 (Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06797518

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Glomerulonephritis, IGA; Immunoglobulin A Nephropathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06797518 (Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06797518

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atypical Hemolytic Uremic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05935215 (Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05935215

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atypical Hemolytic Uremic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05935215 (Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05935215

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: IC-MPGN.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05755386 (Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05755386

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: IC-MPGN.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05755386 (Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05755386

### Jun to Sep 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Primary Immunoglobulin A Nephropathy (IgAN).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06994845 (Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06994845

### June 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Primary Immunoglobulin A Nephropathy (IgAN).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06994845 (Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06994845

## Same indication

- [ADX-097](https://sec-api.dev/pdufa/adx-097) (AKBA)
- [ALXN1720](https://sec-api.dev/pdufa/alxn1720) (AZN)
- [TRUTAKNA (atacicept)](https://sec-api.dev/pdufa/atacicept) (VERA)
- [Vanrafia® (atrasentan)](https://sec-api.dev/pdufa/atrasentan) (NVS)
- [BHV-1400](https://sec-api.dev/pdufa/bhv-1400) (BHVN)
- [Voydeya (danicopan)](https://sec-api.dev/pdufa/danicopan) (AZN)
- [Efgartigimod iv](https://sec-api.dev/pdufa/efgartigimod-iv) (ARGX)
- [Efgartigimod iv or efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-iv-or-efgartigimod-ph20-sc) (ARGX)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [Gefurulimab](https://sec-api.dev/pdufa/gefurulimab) (AZN)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [Oms906 study drug](https://sec-api.dev/pdufa/oms906-study-drug) (OMER)
- [Pozelimab](https://sec-api.dev/pdufa/pozelimab) (REGN)
- [Pozelimab + cemdisiran](https://sec-api.dev/pdufa/pozelimab-cemdisiran) (REGN)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)
- [Remibrutinib (blinded)](https://sec-api.dev/pdufa/remibrutinib-blinded) (NVS)
- [APRIL (telitacicept)](https://sec-api.dev/pdufa/telitacicept) (VOR)
- [Zigakibart](https://sec-api.dev/pdufa/zigakibart) (NVS)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12), [January 2027](https://sec-api.dev/fda-calendar/2027-01), [April 2027](https://sec-api.dev/fda-calendar/2027-04), [October 2027](https://sec-api.dev/fda-calendar/2027-10), [November 2027](https://sec-api.dev/fda-calendar/2027-11), [July 2028](https://sec-api.dev/fda-calendar/2028-07), [October 2028](https://sec-api.dev/fda-calendar/2028-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/iptacopan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FABHALTA® (iptacopan) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/iptacopan

```bibtex
@misc{secapidev_pdufa_iptacopan_20261116,
  title        = {FABHALTA® (iptacopan) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/iptacopan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_iptacopan_20261116","title":"FABHALTA® (iptacopan) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/iptacopan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
